JP7425794B2 - 置換されたインダンを含む固体分散体及び医薬組成物並びにそれの製造方法及び使用 - Google Patents

置換されたインダンを含む固体分散体及び医薬組成物並びにそれの製造方法及び使用 Download PDF

Info

Publication number
JP7425794B2
JP7425794B2 JP2021523218A JP2021523218A JP7425794B2 JP 7425794 B2 JP7425794 B2 JP 7425794B2 JP 2021523218 A JP2021523218 A JP 2021523218A JP 2021523218 A JP2021523218 A JP 2021523218A JP 7425794 B2 JP7425794 B2 JP 7425794B2
Authority
JP
Japan
Prior art keywords
solid dispersion
solid
compound
formula
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021523218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506062A (ja
JP2022506062A5 (https=
Inventor
リンデマン，クリストファー
ステンゲル，ピーター・ジェー
Original Assignee
ペロトン セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ペロトン セラピューティクス， インコーポレイテッド filed Critical ペロトン セラピューティクス， インコーポレイテッド
Publication of JP2022506062A publication Critical patent/JP2022506062A/ja
Publication of JP2022506062A5 publication Critical patent/JP2022506062A5/ja
Application granted granted Critical
Publication of JP7425794B2 publication Critical patent/JP7425794B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2021523218A 2018-10-30 2019-10-23 置換されたインダンを含む固体分散体及び医薬組成物並びにそれの製造方法及び使用 Active JP7425794B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752685P 2018-10-30 2018-10-30
US62/752,685 2018-10-30
PCT/US2019/057725 WO2020092100A1 (en) 2018-10-30 2019-10-23 Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof

Publications (3)

Publication Number Publication Date
JP2022506062A JP2022506062A (ja) 2022-01-17
JP2022506062A5 JP2022506062A5 (https=) 2022-10-20
JP7425794B2 true JP7425794B2 (ja) 2024-01-31

Family

ID=70464349

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523218A Active JP7425794B2 (ja) 2018-10-30 2019-10-23 置換されたインダンを含む固体分散体及び医薬組成物並びにそれの製造方法及び使用

Country Status (9)

Country Link
US (2) US12358870B2 (https=)
EP (1) EP3873443A4 (https=)
JP (1) JP7425794B2 (https=)
KR (1) KR20210091191A (https=)
CN (1) CN112955130A (https=)
MX (1) MX418110B (https=)
MY (1) MY209101A (https=)
SG (1) SG11202104208RA (https=)
WO (1) WO2020092100A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119118872A (zh) 2020-03-19 2024-12-13 艾库斯生物科学有限公司 作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物
WO2021255159A1 (en) * 2020-06-19 2021-12-23 Glaxosmithkline Intellectual Property (No.2) Limited Formulation comprising daprodustat
CA3203975A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
CA3216359A1 (en) 2021-04-07 2022-10-13 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
US11827614B2 (en) 2021-05-21 2023-11-28 Merck Sharp & Dohme Llc Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates
US12145901B1 (en) 2021-09-17 2024-11-19 Arcus Biosciences, Inc. Process for preparing tetralin compounds
AU2023407370A1 (en) * 2022-12-22 2025-07-03 Cogent Biosciences, Inc. Bezuclastinib formulations
AU2024353375A1 (en) 2023-09-29 2026-04-09 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
KR102824931B1 (ko) * 2023-10-17 2025-07-08 주식회사 참인티그레이션 오일 유화 공법을 이용하여 제조되는 반려동물 건강 영양제 및 이의 제조방법
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4932412A (en) 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
EP1223952B1 (en) 1999-10-07 2008-04-16 Carlos Estuardo Aguilar-Cordova Methods for treatment of solid tumors and metastasis by gene therapy
US7115265B1 (en) 2001-05-14 2006-10-03 Duke University Four genetic tumor markers specific for human glioblastoma
PE20091041A1 (es) * 2007-10-19 2009-08-22 Abbott Gmbh & Co Kg Producto de dispersion solida que contiene un compuesto a base de n-aril urea
US8691866B2 (en) * 2008-12-10 2014-04-08 The General Hospital Corporation HIF inhibitors and use thereof
JP6404217B2 (ja) 2012-09-11 2018-10-10 メディベイション プロステイト セラピューティクス エルエルシー エンザルタミドの製剤
WO2015009566A1 (en) * 2013-07-19 2015-01-22 Siga Technologies, Inc. Amorphous tecovirimat preparation
PL3417851T3 (pl) 2013-09-09 2020-12-14 Peloton Therapeutics, Inc. Etery arylowe i ich zastosowanie
EP3089736B1 (en) 2013-12-31 2025-07-23 Ascendia Pharmaceuticals, LLC Pharmaceutical compositions for poorly water-soluble compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GHOSH, Indrajit et al.，Comparison of HPMC based polymers performance as carriers for manufacture of solid dispersions using the melt extruder，International Journal of Pharmaceutics，2011年，419，12-19，DOI:10.1016/j.ijpharm.2011.05.073
NEWMAN, Ann et al.，Assessing the Performance of Amorphous Solid Dispersions，JOURNAL OF PHARMACEUTICAL SCIENCES，2012年，101，1355-1377，DOI:10.1002/jps.23031

Also Published As

Publication number Publication date
MX2021005038A (es) 2021-06-15
SG11202104208RA (en) 2021-05-28
KR20210091191A (ko) 2021-07-21
EP3873443A1 (en) 2021-09-08
US20250326711A1 (en) 2025-10-23
US12358870B2 (en) 2025-07-15
CA3117563A1 (en) 2020-05-07
JP2022506062A (ja) 2022-01-17
MY209101A (en) 2025-06-21
WO2020092100A1 (en) 2020-05-07
EP3873443A4 (en) 2022-07-27
CN112955130A (zh) 2021-06-11
US20210387946A1 (en) 2021-12-16
MX418110B (es) 2024-11-07

Similar Documents

Publication Publication Date Title
JP7425794B2 (ja) 置換されたインダンを含む固体分散体及び医薬組成物並びにそれの製造方法及び使用
JP7801865B2 (ja) 治療活性化合物の医薬組成物
US20200375968A1 (en) Apixaban formulations
JP7269227B2 (ja) ニラパリブ処方物
JP6852073B2 (ja) 悪性病変を処置する方法
JP6524119B2 (ja) 治療活性化合物の医薬組成物
JP2019510746A (ja) 血液学的悪性疾患および固形腫瘍の処置のためのｉｄｈ１阻害剤
US20160082019A1 (en) Drug Combinations to Treat Cancer
CN105377299A (zh) 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法
CA3117563C (en) Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof
RU2772693C1 (ru) Твердые дисперсии и фармацевтические композиции, включающие замещенный индан, и способы их приготовления и применения
JP7287955B2 (ja) シス－４－［２－｛［（３ｓ，４ｒ）－３－フルオロオキサン－４－イル］アミノ｝－８－（２，４，６－トリクロロアニリノ）－９ｈ－プリン－９－イル］－１－メチルシクロヘキサン－１－カルボキサミドの組成物及び使用方法
EA040951B1 (ru) Лекарственные формы цис-4-[2-{[(3s,4r)-3-фтороксан-4-ил]амино}-8-(2,4,6-трихлоранилино)-9н-пурин-9-ил]-1-метилциклогексан-1-карбоксамида и их применение в способе лечения рака
BR112020018697B1 (pt) Composição farmacêutica incluindo alquilsulfato de sódio

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240119

R150 Certificate of patent or registration of utility model

Ref document number: 7425794

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153